Wave Life Sciences (WVE)
NASDAQ:WVE
Want to see WVE full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.3Last Year’s EPS
-0.31Same Quarter Last Year
Strong Buy
Based on 15 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed substantial positive momentum: meaningful revenue growth (largely license-related), improved net loss, strong cash runway, and multiple encouraging clinical readouts and development milestones (notably WVE-007 visceral fat and VMR improvements, advancing WVE-007 into Phase IIa, and WVE-006 demonstrating therapeutically relevant MAAT and regulatory path potential). Headwinds include rising operating expenses, remaining net losses, regulatory and competitive uncertainties, and the need for careful patient enrichment for 007 trials. On balance, the operational and clinical progress and capitalization materially outweigh the listed challenges, but execution risk and competitive dynamics remain important near-term considerations.Company Guidance
Strong Revenue Growth
Q1 2026 revenue of $38.2M versus $9.2M in Q1 2025, a ~315% year-over-year increase driven primarily by recognizing the full amount of revenue associated with regaining full rights to WVE-006 and progress in the GSK collaboration.
Improved Net Loss and Cash Runway
Net loss narrowed to $26.1M in Q1 2026 from $46.9M in Q1 2025 (a ~44% improvement). Company ended the quarter with $544.6M in cash and cash equivalents, which management expects will fund operations into Q3 2028.
WVE-007 Phase I Body Composition Data (INLIGHT)
Single-dose Phase I data (240 mg cohort, 6 months) showed placebo-adjusted visceral fat reduction of 14.3%, total fat reduction of 5.3%, waist circumference reduction of 3.3%, and stable lean mass. Durability demonstrated through at least 7 months supports potential once- or twice-year dosing.
WVE-007 VMR and Competitive Context
Visceral fat-to-muscle ratio (VMR) improved by 16.5% with single-dose 007 — exceeding the 12.2% improvement reported for weekly semaglutide (BELIEVE) and approaching 18.8% observed with comparator vimanrimab — suggesting a differentiated body-composition signal focused on fat loss with muscle preservation.
Advancing WVE-007 into Phase IIa (Multi-dose)
FDA accepted the multi-dose portion of INLIGHT. Phase IIa to start this quarter with global, placebo-controlled multi-dose study enrolling participants BMI 35–50 (with and without T2D), two dose levels (240 mg and 400 mg), four cohorts of 40 patients each (total ~160). Dosing: two doses (Day 1 and Day 85) with 12-month follow-up and primary assessment at Day 85.
WVE-006 RNA Editing Progress and Regulatory Pathway
RestorA-2 interim and ongoing data demonstrate restoration of therapeutically relevant native M-AAT, including generation of >20 µM AAT during an acute phase response; 200 mg biweekly dosing previously restored endogenous MAAT to meaningful levels. Management expects regulatory feedback on a potential accelerated approval pathway mid-2026 and will present expanded 400 mg multiple-dose and 600 mg single-dose data at ATS (May 18).
Pipeline Expansion — WVE-008 and Modalities
WVE-008 (RNA editing for PNPLA3 I148M homozygotes) progressing toward a CTA submission in 2026 to address ~9 million homozygous carriers in US/EU. Company continuing to develop bifunctional constructs and both hepatic and extrahepatic candidates.
Clinical Strategy: Combination & Maintenance Plans
Management is advancing plans to test 007 in combination with incretins and as a maintenance therapy post-incretin this year, leveraging 007's orthogonal mechanism (targeted lipolysis) and muscle preservation to pursue combination and long-term maintenance use cases.
WVE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
WVE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 28, 2026 | $6.94 | $7.52 | +8.36% |
Feb 26, 2026 | $14.54 | $15.36 | +5.64% |
Nov 10, 2025 | $7.86 | $7.05 | -10.31% |
Jul 30, 2025 | $8.32 | $8.16 | -1.92% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Wave Life Sciences (WVE) report earnings?
Wave Life Sciences (WVE) is schdueled to report earning on Jul 30, 2026, TBA (Confirmed).
What is Wave Life Sciences (WVE) earnings time?
Wave Life Sciences (WVE) earnings time is at Jul 30, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is WVE EPS forecast?
WVE EPS forecast for the fiscal quarter 2026 (Q2) is -0.3.
